SCHEMBL7219595

SCHEMBL7219595

PC(c1ccccc1)(c1ccccc1)n1cccn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 2/20 0.51
KCNA3 P22001 1/20 0.51
CYP11B1 P15538 3/20 0.37
CYP11B2 P19099 3/20 0.37
TSHR P16473 3/20 0.33
KMT2A Q03164 2/20 0.33
MAPK1 P28482 2/20 0.32
MAPT P10636 1/20 0.32
HTT P42858 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
ADORA2A P29274 2/20 0.32
HSP90AA1 P07900 1/20 0.32
ADORA3 P0DMS8 1/20 0.32
ADORA2B P29275 1/20 0.32
ADORA1 P30542 1/20 0.32
NPC1 O15118 1/20 0.31
POLB P06746 1/20 0.31
ALDH1A1 P00352 2/20 0.30
MEN1 O00255 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2392374 0.79 KCNN4 (0.69) KCNN4KCNA3CYP11B1CYP11B2TSHR
SCHEMBL28044107 0.72 KCNN4 (0.68) KCNN4KCNA3CYP11B1CYP11B2TSHR
SCHEMBL11143509 0.72 KCNA3 (0.47) KCNN4KCNA3CYP11B1CYP11B2TSHR
SCHEMBL2403558 0.71 KCNN4 (0.58) KCNN4KCNA3CYP11B1CYP11B2TSHR
SCHEMBL20772229 0.71 KCNN4 (0.58) KCNN4KCNA3CYP11B1CYP11B2TSHR
SCHEMBL11501302 0.71 KCNN4 (0.46) KCNN4KCNA3CYP11B1CYP11B2KMT2A
SCHEMBL1750941 0.71 KCNN4 (0.58) KCNN4KCNA3CYP11B1CYP11B2TSHR
SCHEMBL2391892 0.71 KCNN4 (0.58) KCNN4KCNA3CYP11B1CYP11B2TSHR
SCHEMBL2361042 0.71 KCNN4 (0.67) KCNN4KCNA3CYP11B1CYP11B2TSHR
SCHEMBL27693137 0.70 KCNN4 (0.42) KCNN4KCNA3TSHRKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6627758-B2 Ligand including (i) at least two different types of heteroatoms selected from nitrogen, phosphorus, and sulfur, and (ii) at least one of imidazole, pyrazole, and pyridine; transition metal complex for carbonylation to aldehyde SAN DIEGO STATE UNIVERSITY FOUNDATION 2003-09-30 US disclosed
US-20020115860-A1 Compositions and methods for hydration of terminal alkynes SAN DIEGO STATE UNIVERSITY FOUNDATION (US) 2002-08-22 US disclosed
US-6380393-B1 COMPLEX CONTAINING PYRAZOLE RING SAN DIEGO STATE UNIVERSITY FOUNDATION 2002-04-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115860-A1 Compositions and methods for hydration of terminal alkynes CYCS, MYB, POLN KCNN4 111/4885KCNA3 760/4885CYP11B1 3645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.